Memorial Şişli Hospital
Neuroblastoma treatment cost in Turkey typically starts with essential diagnostics like MIBG-scintigraphy, which costs Price on request to Price on request . For primary care, complex treatment of neuroblastoma runs from AUD $39,330 to AUD $58,995. Total expenses depend on the cancer stage and required chemotherapy cycles. Patients generally save 40–70% compared to Australia or the US. Key treatment hubs include Istanbul, Ankara, and Antalya.
Typical Neuroblastoma Treatment Costs in Turkey
Bookimed Expert Insight: Australian families seeking high-precision care should consider clinics with heavy technology investments. Medipol Mega University Hospital uses CyberKnife and Gamma Knife for non-invasive tumour targeting. For advanced systemic cases, Medical Park Antalya specialises in immunotherapy. This clinic is a frequent choice for Australians. For surgical expertise, Professor Ahmet Demir has over 20 years of experience managing childhood neuroblastoma cases.
| Turkey | Thailand | ||
| Complex treatment of neuroblastoma | from AUD $39,330 | from AUD $63,209 | from AUD $34,414 |
Professor Ceyhun Bozkurt is a leading paediatric haematology-oncology specialist who trained at the Harvard-affiliated Dana-Farber Cancer Institute. He currently serves as the Clinical Director at Medical Park Bahcelievler.
Professor Ahmet Demir is a high-level specialist in paediatric oncology who leads treatment for complex childhood cancers at Memorial Ankara Hospital.
Dr. Ahmet Nadir Tosyali is a pediatric surgeon at Anadolu Medical Center in Istanbul. He holds the Turkish Pediatric Surgery Qualification Certificate. Dr. Tosyali treats complex conditions like Wilms tumor, neuroblastoma, and spina bifida. He provides care at a clinic affiliated with Johns Hopkins Medicine.
Professor Yesim Yildirim is a leading medical oncologist at Anadolu Medical Center, specialising in targeted therapies and immunotherapy protocols for complex paediatric and adult cases.
International families choose Turkey for neuroblastoma care. The country offers high-volume paediatric oncology centres and access to therapies. Leading hospitals provide specialised bone marrow transplants, immunotherapy, and robotic surgery. These come at a fraction of the cost found in the United States or Western Europe.
Bookimed Expert Insight: Turkey has a unique concentration of paediatric bone marrow units within general oncology centres. Hisar Hospital Intercontinental, for example, treats 250,000 patients annually. It offers allogeneic, autologous, and haploidentical transplants in HEPA-filtered rooms. This infrastructure allows specialists to move from initial chemotherapy to stem cell rescue. There is no need to transfer the child between facilities.
Patient Consensus: Patients note that staging and scans happen very quickly in Turkey. This provides relief during a time-sensitive diagnosis. Families appreciate the fixed translators and friendly staff. They help navigate the journey from the airport to the operating theatre.
Turkish specialists treat neuroblastoma using a risk-adapted multimodal strategy. They combine surgery, high-dose chemotherapy, and autologous stem cell transplantation. Specialised clinics use targeted immunotherapy and radiotherapy to clear residual disease. These protocols align with international standards like the Children's Oncology Group (COG) for paediatric care.
Bookimed Expert Insight: Turkish paediatric oncology stands out due to the high volume of complex stem cell transplants. Hisar Hospital Intercontinental alone treats 250,000 patients annually and operates a specialised bone marrow unit with HEPA-filtered rooms. This infrastructure is vital for neuroblastoma patients. Consolidation therapy requires a sterile environment to prevent infections while the immune system recovers.
Patient Consensus: Patients note that staging tests like PET-CT and MIBG scans are performed quickly in Istanbul. Families value the multidisciplinary tumour boards where surgeons and oncologists collaborate to explain the child's risk category in simple terms.
High-risk neuroblastoma treatment in Turkey follows a standardised 18-month roadmap. It involves induction chemotherapy, surgical resection, and consolidation via bone marrow transplant. Major JCI-accredited centres use MIBG-scintigraphy and PET-CT to monitor progress. Examples include Memorial Ankara Hospital and Anadolu Medical Center. This intensive approach maintains high 5-year survival rates for paediatric cases.
Bookimed Expert Insight: Turkish oncology centres often provide a clinical advantage by hosting multidisciplinary tumour boards that include paediatric surgeons like Dr Ahmet Nadir Tosyali. Centres such as Hisar Hospital Intercontinental perform allogeneic and haploidentical transplants, which are critical if a child’s own stem cells are not viable. This integrated approach means the entire roadmap occurs within one facility.
Patient Consensus: Families in Turkey emphasise the speed of staging tests and the clarity of risk-category explanations. They note that having an English-speaking coordinator helps manage the long-term transition. This transition goes from surgery to maintenance therapy.